CD7 CAR-T
/ Guangzhou Bio-gene Technology
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 18, 2026
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
(clinicaltrials.gov)
- P1/2 | N=0 | Withdrawn | Sponsor: Guangzhou Bio-gene Technology Co., Ltd | N=30 ➔ 0 | Active, not recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • CD7
July 27, 2023
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
(clinicaltrials.gov)
- P1/2 | N=30 | Active, not recruiting | Sponsor: Guangzhou Bio-gene Technology Co., Ltd | Recruiting ➔ Active, not recruiting | Initiation date: Aug 2023 ➔ May 2023
Enrollment closed • Trial initiation date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • CD7
July 10, 2023
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
(clinicaltrials.gov)
- P1/2 | N=30 | Recruiting | Sponsor: Guangzhou Bio-gene Technology Co., Ltd | Phase classification: P=N/A ➔ P1/2
Phase classification • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • CD7
1 to 3
Of
3
Go to page
1